124-90-3

Basic information

• Product Name: OXYCODONE HYDROCHLORIDE
• Synonyms: OXYCODONE HCL;OXYCODONE HYDROCHLORIDE;14-hydroxydihydrocodeinonehydrochloride;4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-onhydrochloride;4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-morphinan-6-one,hydrochloride,(5-a;dihydronehydrochloride;dihydrooxycodeinonehydrochloride;dihydroxycodeinonehydrochloride
• CAS NO: 124-90-3
• Molecular Formula: C₁₈H₂₁NO₄*ClH
• Molecular Weight: 351.82
• EINECS: 204-717-1
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 124-90-3.mol
• Article Data: 15

Chemical Properties

• Melting Point: 261-2630C
• Boiling Point: 501.6 °C at 760 mmHg
• Flash Point: 11℃
• Appearance: White solid
• Density: 1.39 g/cm³
• Vapor Pressure: 7.02E-11mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: Freely soluble in water, sparingly soluble in anhydrous ethanol, practically insoluble in toluene.
• Water Solubility: 142.9g/L(temperature not stated)
• CAS DataBase Reference: OXYCODONE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: OXYCODONE HYDROCHLORIDE(124-90-3)
• EPA Substance Registry System: OXYCODONE HYDROCHLORIDE(124-90-3)

Safety Data

• Hazard Codes: Xn,T,F
• Statements: 22-39/23/24/25-23/24/25-11
• Safety Statements: 36/37-45-16-7
• RIDADR: UN 1230 3/PG 2
• WGK Germany: 3
• RTECS: QD2470000
• HazardClass: 6.1(a)
• PackingGroup: II
• Hazardous Substances Data: 124-90-3(Hazardous Substances Data)

Usage

Description

Oxycodone (hydrochloride) (Item No. 26513) is an analytical reference standard categorized as an opioid. Oxycodone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

Chemical Properties

White Solid

Originator

Oxyfast,Purdue Pharma, L.P.

Uses

Controlled substance (opiate). Analgesic (narcotic)

Brand name

Oxycontin (Purdue); Roxicodone (Roxane); Roxicodone (Xanodyne).

Therapeutic Function

Narcotic analgesic

Biological Activity

Potent and selective μ -opioid receptor agonist (K i values are 16 and >1000 nM for hMOR1 and hKOR1 respectively).

Clinical Use

Oxycodone is about equipotent with morphine, but because of the 3-OCH group, it has a much lower oral:parenteral dose ratio. Thus, oxycodone is used orally to treat severe to moderate pain. It is a drug as a single agent and when combined in strong analgesic mixtures. Oxycodone has a plasma half-life of approximately 4 hours and requires dosing every 4 to 6 hours.

Drug interactions

Potentially hazardous interactions with other drugs Analgesics: possible opioid withdrawal with buprenorphine and pentazocine. Antibacterials: metabolism possibly increased by rifampicin; metabolism inhibited by telithromycin. Antidepressants: CNS excitation or depression with MAOIs - avoid; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics. Antifungals: concentration increased by voriconazole. Antihistamines: increased sedative effects with sedating antihistamines. Antipsychotics: enhanced hypotensive and sedative effects. Antivirals: concentration possibly increased by ritonavir. Dopaminergics: avoid with selegiline. Nalmefene: avoid concomitant use. Sodium oxybate: enhanced effect of sodium oxybate - avoid.

Metabolism

Oxycodone is metabolised in the liver to produce noroxycodone via the CYP3A system, oxymorphone via the CYP2D6 system and various conjugated glucuronides. The analgesic effects of the metabolites are clinically insignificant. Both metabolites undergo glucuronidation and are excreted with unchanged drug in urine.

InChI:InChI=1/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

Upstream product

• 5985-56-8 14-hydroxycodeinone hydrochloride 
• 115-37-7 thebaine 
• 865844-01-5 8α-hydroxyoxycodone 
• 76-42-6 Oxycodone 
• 508-54-3 14-hydroxycodeinone 

Downstream Products

• 76-42-6 Oxycodone 
• 57664-96-7 noroxycodone 
• 357-07-3 oxymorphone hydrochloride 
• 357-08-4 naloxone hydrochloride 
• 145301-15-1 (6R,6aS,8R,12R,12aS)-(-)-1,12-Epoxy-5,6,6a,7,8,11-hexahydro-6a-hydroxy-6,12a-iminoethano-2-methoxy-10,15-dimethyl-8-(3-nitrophenyl)-(12H)-naphtho<2,1-g>chinolin-9-carbonsaeureethylester 
• 145301-15-1 (6R,6aS,8S,12R,12aS)-(-)-1,12-Epoxy-5,6,6a,7,8,11-hexahydro-6a-hydroxy-6,12a-iminoethano-2-methoxy-10,15-dimethyl-8-(3-nitrophenyl)-(12H)-naphtho<2,1-g>chinolin-9-carbonsaeureethylester 
• 145301-14-0 (6R,6aS,8R,12R,12aS)-(-)-1,12-Epoxy-5,6,6a,7,8,11-hexahydro-6a-hydroxy-6,12a-iminoethano-2-methoxy-10,15-dimethyl-8-(3-nitrophenyl)-(12H)-naphtho<2,1-g>chinolin-9-carbonsaeuremethylester 
• 145301-14-0 (6R,6aS,8S,12R,12aS)-(-)-1,12-Epoxy-5,6,6a,7,8,11-hexahydro-6a-hydroxy-6,12a-iminoethano-2-methoxy-10,15-dimethyl-8-(3-nitrophenyl)-(12H)-naphtho<2,1-g>chinolin-9-carbonsaeuremethylester 
• 76-41-5 oxymorphone 
• 52446-25-0 noroxyoxycodone hydrochloride 

Related news

Original ReportSafety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily OXYCODONE HYDROCHLORIDE (cas 124-90-3) Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study10/01/2019

Noninferiority of the efficacy of once-daily hydromorphone hydrochloride extended-release (hydromorphone ER) compared with twice-daily oxycodone hydrochloride controlled-release (oxycodone CR) was investigated in this randomized, double-blind study in Chinese patients with moderate to severe can...detailed

Original ArticleMicrobiological and Physicochemical Stability of OXYCODONE HYDROCHLORIDE (cas 124-90-3) Solutions for Patient-Controlled Delivery Systems09/10/2019

ContextThe use of patient-controlled analgesia (PCA) allows patients to be managed at home and may increase the quality of life of patients with regard to drug administration. To ensure that intact drug is delivered to the patient in this setting, it is important to study its microbiological and...detailed

Original research articlePharmacokinetics of OXYCODONE HYDROCHLORIDE (cas 124-90-3) and three of its metabolites after intravenous administration in Chinese patients with pain09/09/2019

ObjectivesThe aim of this study is to evaluate the pharmacokinetic profile of oxycodone and three of its metabolites, noroxycodone, oxymorphone and noroxymorphone after intravenous administration in Chinese patients with pain.detailed

Case ReportPremedication with fast-acting OXYCODONE HYDROCHLORIDE (cas 124-90-3) hydrate effectively reduced oxaliplatin-induced severe vascular pain09/08/2019

Oxaliplatin is a platinum-based chemotherapeutic agent that holds a prominent position in the treatment of colorectal and gastric cancers. However, severe oxaliplatin-related vascular pain can be problematic for patients. Here we describe seven patients who experienced severe vascular pain cause...detailed

Relevant articles and documents

Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone

Improved processes for making opioid products having low impurity levels including making 14-hydroxycodeinone and 14-hydroxymorphinone from thebaine and oripavine, respectively.

CONVERSION OF OXYCODONE BASE TO OXYCODONE HYDROCHLORIDE

Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity. Efficient methods for conversion of oxycodone base to oxycodone hydrochloride are provided to minimize 14-hydroxycodeinone impurity in the final product.

A METHOD FOR PREPARING OXYCODONE

The present invention provides a process for preparing an oxycodone acid adduct, said process comprising hydrogenating an aqueous solution of 14-hydroxycodeinone and an acid to form a solution of the oxycodone acid adduct, wherein the hydrogenation is carried out at one or more temperatures greater than ambient temperature in the presence of a hydrogenation catalyst and hydrogen gas, wherein the solution of oxycodone acid adduct comprises 6α-oxycodol in an amount ≤ about 0.800 area % as determined by HPLC.